Salarius Pharmaceuticals (NASDAQ:SLRX – Get Rating) and Orgenesis (NASDAQ:ORGS – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.
Profitability
This table compares Salarius Pharmaceuticals and Orgenesis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Salarius Pharmaceuticals | N/A | -138.54% | -112.56% |
| Orgenesis | -35.18% | -41.99% | -15.89% |
Risk & Volatility
Salarius Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.
Institutional and Insider Ownership
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Salarius Pharmaceuticals and Orgenesis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Salarius Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| Orgenesis | 0 | 0 | 1 | 0 | 3.00 |
Orgenesis has a consensus target price of $6.00, indicating a potential upside of 376.19%. Given Orgenesis’ higher possible upside, analysts plainly believe Orgenesis is more favorable than Salarius Pharmaceuticals.
Earnings and Valuation
This table compares Salarius Pharmaceuticals and Orgenesis’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Salarius Pharmaceuticals | $1.84 million | 2.62 | -$31.61 million | ($13.72) | -0.11 |
| Orgenesis | $35.86 million | 1.00 | -$14.89 million | ($0.50) | -2.52 |
Orgenesis has higher revenue and earnings than Salarius Pharmaceuticals. Orgenesis is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Orgenesis beats Salarius Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
About Orgenesis
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
